Teva Pharmaceuticals announced during the 22nd Annual Global Healthcare Conference held yesterday that confidence interval 99% of the targeted injections for submission have been performed. Teva also confirmed that the full submission safety results are expected to be available in the second half. Olanzapine LAI is an investigational once-monthly subcutaneous long-acting injection of the atypical antipsychotic Olanzapine. Teva is fully responsible for leading the development and commercialization of Olanzapine LAI. Medincell may receive up to $117M in development and commercial milestones for mdc-TJK, in addition to royalties on all net sales of both products.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA: